CDKN2A and glioblastoma: Beyond cell cycle control: &lt;i&gt;CDKN2A&lt;/i&gt; loss is associated with altered NAD&lt;sup&gt;+&lt;/sup&gt; metabolic states and increased sensitivity to NAMPT inhibition in glioblastoma.